U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07732309) titled 'A Study of ATG-201 in Adult Participants With Autoimmune Diseases' on July 24.
Brief Summary: This is a phase I, open-label study of ATG-201 in participants with autoimmune diseases.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Systemic Sclerosis (SSc)
Sjogren's Disease
Intervention:
DRUG: ATG-201
ATG-201 is a recombinant, human IgG1-like TCE that simultaneously binds to human CD3 and CD19. The primary packaging used for ATG-201 injection consists of 2 mL middle-boro injection vial (2 mL-Pro), sealed with 13 mm stopper gray with B2 coating and 13 FO LQ 3769 blue cap. The produc...